Ownership and insider activity for Upstream Bio, Inc. (UPB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
Price
| Price | $5.33 |
| Market Cap | $290M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $17.1M | $25.8M | $325.9M | $101.6M |
| Short-term Investments | 0 | $84.0M | $144.6M | $239.9M |
| Receivables | $412000 | $236000 | $1.2M | $668000 |
| Inventory | 0 | 0 | 0 | 0 |
| Total Current Assets | $18.3M | $117.0M | $479.2M | $351.8M |
| Property, Plant & Equipment | $164000 | $202000 | $2.4M | $1.8M |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Total Assets | $18.5M | $117.2M | $481.7M | $353.8M |
| Accounts Payable | $712000 | $2.0M | $4.0M | $2.7M |
| Short-term Debt | 0 | 0 | 0 | $720000 |
| Total Current Liabilities | $4.9M | $6.5M | $10.7M | $13.5M |
| Long-term Debt | 0 | 0 | 0 | $549000 |
| Total Liabilities | $124.6M | $240.3M | $11.9M | $14.0M |
| Retained Earnings | -$107.4M | -$128.0M | -$190.8M | -$334.2M |
| Total Equity | -$106.2M | -$123.1M | $469.9M | $339.8M |
| Total Debt | $94000 | $45000 | $1.8M | $1.3M |
| Net Debt | -$17.0M | -$109.8M | -$468.6M | -$340.2M |
| Working Capital | $13.5M | $110.5M | $468.4M | $338.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 27.99 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 60.99 |
Profitability
| Return on Equity | -42.22% |
| Return on Invested Capital | -47.02% |
| Return on Assets | -40.55% |
| Gross Margin | 98.45% |
| Operating Margin | -5382.65% |
| Net Margin | -4955.67% |
Related companies: AMLX · NTLA · NVAX · PHVS · RLAY · SNDX · SYRE
Explore sector: Healthcare · Biotechnology
More sections of UPB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks